102 results on '"OVERALL survival"'
Search Results
2. Immune Therapy, EGFR Inhibition Take Hold of Stage III NSCLC.
3. New Data Augment the Treatment Paradigm in HR+/HER2- Breast Cancer.
4. Adding Chemotherapy to Frontline Osimertinib Is Under Debate in EGFR-Mutated NSCLC..
5. Perioperative Pembrolizumab/ Chemo Regimen Yields Superior OS in Resectable Gastric Cancer.
6. 18-Month Survival Results of Neoadjuvant Cemiplimab in Advanced Resectable CSCC May Lead to Reconsideration of Adjuvant Treatment.
7. Belzutifan Improves PFS in ccRCC Subgroups.
8. Impactful Studies Challenge the Status Quo at GI Conference.
9. Novel Approaches Focus on Limiting Toxicity in Older Patients with ALL.
10. Serial ctDNA Testing Could Improve Risk Stratification in High-Risk MIBC.
11. Expanding 177Lutetium-PSMA-617 Use in the Community.
12. Blinatumomab Receives Approval for CD19+ B-ALL in the Consolidation Phase.
13. 2023 ASCO Genitourinary Cancers Symposium Data at a Glance.
14. 2023 World Conference on Lung Cancer.
15. Clinical Updates: KIDNEY CANCER. Updated data show OS benefit with adjuvant pembrolizumab in ccRCC.
16. Afami-Cel Receives Accelerated Approval for Advanced Synovial Sarcoma: Accelerated approval has been granted by the FDA to afamitresgene autoleucel for certain patients with pretreated unresectable or metastatic synovial sarcoma.
17. Clinical Updates: PROSTATE CANCER. Darolutamide delays time to progression from mHSPC to mCRPC vs placebo.
18. Clinical Updates: PROSTATE CANCER. Survival may be improving in de novo mHSPC, new data suggest.
19. Clinical Updates: BLADDER CANCER. Adding durvalumab to chemotherapy extends survival in MIBC.
20. The Benefits of Elacestrant in HR+/HER2– Metastatic Breast Cancer Subgroups.
21. Chemotherapy/Pembrolizumab Improves pCR in Key ER+ Breast Cancer Subgroups.
22. Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials.
23. From the Co-Editor in Chief: BCG-unresponsive NMIBC: Advancements are moving the needle.
24. A Treatment Evolution Is Underway in BRAF V600E-Mutated mCRC: Investigators continue to explore new ways to manage colorectal cancer with a BRAF V600E mutation.
25. Abemaciclib, NSAI Extend Overall Survival for Patients With Hormone Receptor--Positive, HER2-Negative Advanced Breast Cancer.
26. Survival Outcomes and PROs Favor Cemiplimab + Chemotherapy vs Chemotherapy Alone in Advanced NSCLC Regardless of PD-L1 Status.
27. Induction Chemotherapy Prior to Chemoradiation Represents Potential New SOC in Locally Advanced Cervical Cancer.
28. Why MRD Falls Short as a Frontline CLL End Point--For Now.
29. Triplet vs SOC Explored in Metastatic Prostate Cancer.
30. Mirvetuximab Soravtansine Shows Efficacy in Ovarian Cancer Despite Dose Adjustments.
31. Lenvatinib and Pembrolizumab Combo Breaks New Ground in Non–Clear Cell RCC.
32. Paclitaxel/Ramucirumab Prolongs Survival in Gastric Cancer.
33. Blue light cystoscopy decreases risk of recurrence, progression in NMIBC.
34. Atara Submits BLA for Cell Therapy for Post-Transplant Complication.
35. Perioperative Chemotherapy With FLOT Improves OS in Resectable Esophageal Cancer.
36. Evaluating the Role of Neoadjuvant Sacituzumab Govitecan in Bladder Cancer.
37. Unlocking Latest Insights Into HR-Positive, HER2-Negative Treatment Strategies.
38. Linvoseltamab Delivers Deep, Durable Responses in R/R Multiple Myeloma.
39. Amivantamab/Chemotherapy Prolongs Progression-Free Survival in NSCLC.
40. FDA Committee Agrees That MRD Is a Viable End Point in Myeloma Trials.
41. Nogapendekin alfa inbakicept-pmln (N-803; Anktiva).
42. First-Line Durvalumab Improves PFS in Advanced Endometrial Cancer.
43. Pembrolizumab Combination Shows Positive OS Trend in Endometrial Cancer.
44. Combining Avutometinib With Defactinib Yields High Response Rates in LGSOC.
45. FDA Grants Full Approval to Elahere.
46. Novel Drug Granted FDA FAST TRACK DESIGNATION.
47. FDA Withdraws Approval of Pepaxto in Multiple Myeloma.
48. FDA Sets Date for First-in-Class Lung Cancer Therapy.
49. FDA Approves Onivyde for First-line Metastatic Pancreatic Cancer.
50. FDA Sets Advisory Meeting for Abecma in Supplemental Multiple Myeloma Indication.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.